Back to news
BUSINESSThe Dales Report

The Dales Report examines High Tide growth and Schedule III compliance

The Dales Report reviewed High Tide's record third-quarter revenue and asset-light U.S. ambitions, then discussed Schedule III operational issues including DEA registration, product consistency, drug-interaction screening and the limits of automatic insurance coverage. Oklahoma operators get both a competitive public-company signal and a practical checklist for medical-market compliance planning.

Share this update

FacebookXLinkedInEmail

#national#capital#rescheduling#compliance#medical-cannabis#market-data

Read the original source

Leafy summaries provide industry context. Confirm details with The Dales Report.

Open source

Continue reading

Related industry updates